Novel intravenous antithrombins

American Heart Journal

Volumn 141, Issue 6, 2001, Pages 1043-1047

  Levy, Jerrold H ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; ANTITHROMBIN III CONCENTRATE; ARGATROBAN; DALTEPARIN; DANAPAROID; DERMATAN SULFATE; ENOXAPARIN; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; ORGANON; RECOMBINANT HIRUDIN;

ANTICOAGULANT THERAPY; BLOOD CLOTTING TIME; CONFERENCE PAPER; HEART SURGERY; HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBIN TIME; THROMBOGENESIS; THROMBOSIS;

EID: 0035370899     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2001.115526     Document Type: Conference Paper

References (68)

1. Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992;326:800-6.
2. Hirsh J. Heparin. N Engl J Med 1991;324:1565-74.
3. Harker LA, Hanson SR, Runge MS. Thrombin hypothesis of thrombus generation and vascular lesion formation. Am J Cardiol 1995;75:12-7B.
4. Turpie AGG, Weitz JI, Hirsh J. Advances in antithrombotic therapy: novel agents. Thromb Haemost 1995;74:565-71.
5. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991;30:10363-70.
6. Cairns J, Lewis HD Jr, Meade TW, et al. Anti-thrombotic agents in coronary artery disease. Chest 1995;108:380-4005.
7. Willerson JT. Conversion from chronic to acute coronary heart disease syndromes: role of platelets and platelet products. Tex Heart Inst J 1995;22:13-9.
8. Miller BE, Levy JH. The inflammatory response to cardiopulmonary bypass. J Cardiothorac Anesth 1997;11:355-66.
9. Cicala C, Cirino G. Linkage between inflammation and coagulation: an update on the molecular basis of the crosstalk. Life Sci 1998;62:1817-24.
10. Strukova SM, Dugina TN, Khlgatian SV, et al. Thrombin-mediated events implicated in mast cell activation. Semin Thromb Hemost 1996;22:145-50.
11. Hirsh J, Fuster V. Guide to anticoagulation therapy, I: heparin. Circulation 1994;89:1449-68.
12. Danielsson A, Raub E, Lindahl U, et al. Role of ternary complexes, in which heparin binds both antithrombin and proteinase in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem 1986;261:15467-73.
13. Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997;95:594-9.
14. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79:1-17.
15. Antman EM, TIMI 9A Investigators. Hirudin in acute myocardial infarction: safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI 9A) trial. Circulation 1994;90:1624-30.
16. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIA Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631-7.
17. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIB Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-82.
18. Lewis BE, Walenga JM, Wallis DE. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Hemost 1997;23:197-202.
19. Hirsh J, Raschke R, Warkentin TE, et al. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 1995;108(Suppl):258-75S.
20. Antman EM, Handin R. Low-molecular-weight heparins: an intriguing new twist with profound implications. Circulation 1998;98:287-9.
21. Levy JH, Kelly AB. ACT and antithrombin effects. Circulation 1997;96:14-5.
22. Brister SJ, Buchanan MR. Heparinless cardiopulmonary bypass revisited: a newer strategy to avoid heparin-related bleeding using dermatan sulfate. J Cardiothorac Vasc Anesth 1995;9:317-21.
23. Bagge L, Holmer E, Wahlberg T, et al. Fragmin (LMWH) vs heparin for anticoagulation during in vitro recycling of human blood in cardiopulmonary bypass circuits: dose-dependence and mechanisms of clotting. Blood Coagul Fibrinol 1994;5:273-80.
24. Henny CP, Ten Cate H, Ten Cate JW, et al. A randomized blind study comparing standard heparin and a new low molecular weight heparinoid in cardiopulmonary bypass surgery in dogs. J Lab Clin Med 1985;106:187-96.
25. Stiekema JC, Wijnand HP, Van Dinther TG, et al. Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers. Br J Clin Pharmacol 1989;27:39-48.
26. Ortel TL, Gockerman JP, Califf RM, et al. Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis. Thromb Haemost 1992;67:292-6.
27. Doherty DC, Ortel TL, de Bruijn N, et al. "Heparin-free" cardiopulmonary bypass: first reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass. Anesthesiology 1990;73:562-5.
28. Magnani HN. Heparin-induced thrombocytopenia (HIT): an over-view of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993;70:554-61.
29. Ganjoo AK, Harloff MG, Johnson WD. Cardiopulmonary bypass for heparin-induced thrombocytopenia: management with a heparinbonded circuit and enoxaparin. J Thorac Cardiovasc Surg 1996; 112:1390-2.
30. Robitaille D, Ledere JR, Laberge R, et al. Cardiopulmonary bypass with a low-molecular-weight heparin fraction (enoxaparin) in a patient with a history of heparin-associated thrombocytopenia. J Thorac Cardiovasc Surg 1992;103:597-9.
31. Mochizuki T, Olson PJ, Ramsay JG, et al. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg 1998;87:781-5.
32. Bucur SZ, Levy JH, Despotis GJ, et al. Uses of antithrombin III concentrate in congenital and acquired deficiency states. Transfusion 1998;38:481-98.
33. Dietrich W, Spannagl M, Schramm W, et al. The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991;102:505-14.
34. Despotis GJ, Levine V, Joist JH, et al. Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation. Anesth Analg 1997;85:498-506.
35. Staples MH, Dunton TF, Karlson KJ, et al. Heparin resistance after preoperative heparin therapy or intraaortic balloon pumping. Ann Thorac Surg 1994;57:1211-6.
36. Zaidan JR, Johnson S, Brynes R, et al. Rate of protamine administration: its effect on heparin reversal and antithrombin recovery after coronary artery surgery. Anesth Analg 1986;65:377-80.
37. Levy JH, Despotis GJ, Olson PJ, et al. Recombinant human transgenic antithrombin in cardiac surgery. Anesthesiology. In press.
38. Markwardt F. Hirudin: the promising antithrombotic. Cardiovasc Drug Rev 1992;10:211-32.
39. Weitz JI, Huboda M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-91.
40. Neuhaus KL, von Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. Circulation 1994;90:1638-42.
41. Arnoletti JP, Whitman GJ. Heparin-induced thrombocytopenia in coronary bypass surgery. Ann Thor Surg 1999;68:576-8.
42. Fareed J, Callas D, Hoppensteadt DA, et al. Antithrombin agents as anticoagulants and antithrombotics: implications in drug development. Semin Hematol 1999;36(1 Suppl):42-56.
43. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999;99:73-80.
44. Potzsch B, Madlener K, Seelig C, et al. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass: assessment of the whole blood ecarin clotting time. Thromb Haemost 1997;77:920-5.
45. Kong DF, Topol EJ, Bittl JA, et al. Clinical outcomes of bivalirudin for ischemic heart disease. Circulation 1999;100:2049-53.
46. Turpie AG. Anticoagulants in acute coronary syndromes. Am J Cardiol 1999;84:2-6M.
47. Pineo GF, Hull RD. Thrombin inhibitors as anticoagulant agents. Curr Opin Hematol 1999;6:298-303.
48. Despotis GJ, Filos K, Gravlee G, et al. Anticoagulation monitoring during cardiac surgery: a survey of current practice and review of current and emerging techniques. Anesthesiology 1999;91:1122-51.
49. Jobes DR, Schwartz AJ, Ellison et al. Monitoring heparin anticoagulation and its neutralization. Ann Thorac Surg 1980;31:161-6.
50. Despotis GJ, Summerfield AL, Joist JH, et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994;108:1076-82.
51. Cohen EJ, Cameriengo LJ, Dearing JP. Activated clotting times and cardiopulmonary bypass, I: the effect of hemodilution and hypothermia upon activated clotting time. J Extracorp Tech 1980;12:139-41.
52. Stenbjerg S, Berg E, Albrechtsen OK. Heparin levels and activated clotting time (ACT) during open heart surgery. Scand J Haematol 1981;26:281-4.
53. Culliford AT, Gitel SN, Starr N, et al. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Thorac Surg 1981;193:105-11.
54. Moorehead MT, Westengard JC, Bull BS. Platelet involvement in the activated coagulation time of heparinized blood. Anesth Analg 1984;63:394-8.
55. Moliterno DJ, Califf RM, Aguirre FV, et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial): evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 1995;75:559-62.
56. Wang JS, Lin CY, Hung WT, et al. Monitoring of heparin-induced anticoagulation with kaolin-activated clotting time in cardiac surgical patients treated with aprotinin. Anesthesiology 1992;77:1080-4.
57. Wendel HP, Heller W, Gallimore MJ, et al. The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement. Blood Coag Fibrinol 1993;4:41-5.
58. Ammar T, Scudder LE, Coller BS. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation 1997;95:614-7.
59. Sane DC, Gresalfi NJ, Enney-O'Mara LA, et al. Exploration of rapid bedside monitoring of coagulation and fibrinolysis parameters during thrombolytic therapy. Blood Coagul Fibrinol 1992;3:47-54.
60. Walenga JM, Bakhos M, Messmore HL, et al. Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass model. Ann Thorac Surg 1991;51:271-7.
61. Riess FC, Lower C, Seelig C. Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: successful for aortic valve replacement in man. J Thorac Cardiovasc Surg 1995;110:265-7.
62. Riess FC, Potzsch B, Bader R. A case report on the use of recombinant hirudin as an anticoagulant for cardiopulmonary bypass in open-heart surgery. Eur J Cardiothorac Surg 1996;10:386-8.
63. Matsuo T, Kario K, Chikahira Y, et al. Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor. Br J Haematol 1992;82:627-9.
64. Chomiak PN, Walenga JM, Koza MJ, et al. Investigation of a thrombin inhibitor peptide as an alternative to heparin in cardiopulmonary bypass surgery. Circulation 1993;88:407-12.
65. DeAnda A Jr, Coutre S, Miller DC. Synthetic peptide thrombin inhibitor. Circulation 1994;90:1581-2.
66. Preiss DU, Schneider Y, Scholz ME, et al. Pentosanplysulfate (PPS) an alternative anticoagulant for cardiopulmonary bypass in heart surgery [abstract]. Anesth Analg 1997;84:105.
67. Schneider Y, Obolenski S, Preiss DU, et al. Pentoanpolysulfate (PPS), a substitute for heparin in extracorporeal circulation (ECC) [abstract]. Acta Anaesth Scand 1997;40:221.
68. Lenting PJ, Meijerman DWE, Clijsters PPFM, et al. A novel antithrombotic strategy based on inhibitors of factor VIII-factor IX complex assembly [abstract]. Thromb Haemost 1997;77:689.